A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00000854
First received: November 2, 1999
Last updated: February 13, 2012
Last verified: February 2012

November 2, 1999
February 13, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00000854 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss
A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Trial of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

The purpose of this study is to see if giving nandrolone decanoate (a hormonal drug) will cause weight gain in HIV-positive women who have HIV-associated weight loss (wasting).

Wasting has become an AIDS-defining condition. In the past, most studies that examined wasting treatments were limited to men. However, it appears that wasting in HIV-positive men is linked to levels of testosterone (a hormone which affects men's bodies more than women's). This study has been designed for women only, in order to best treat wasting in HIV-positive women.

Body wasting is an increasingly frequent AIDS-defining condition and it is becoming evident that women are not exempt from this complication of HIV. Although multicenter trials of megestrol acetate, dronabinol and growth hormone have not specifically excluded women, women have generally been underrepresented in these trials. This study hopes to generate data that will be substantial enough to perform an analysis that might determine whether there are gender-based differences in anabolic potential.

Patients will be randomized to receive either nandrolone decanoate or placebo every 2 weeks for 12 weeks of the study. All patients who complete the first 12 weeks of the study will be eligible to receive open-label nandrolone for the subsequent 12 weeks.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
  • HIV Infections
  • HIV Wasting Syndrome
Drug: Nandrolone decanoate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
May 2003
Not Provided

Inclusion Criteria

You may be eligible for this study if you:

  • Are an HIV-positive woman over 13 years old (need consent if under 18).
  • Have lost weight over the past 12 months.
  • Are able to eat almost enough to maintain your current weight.
  • Agree to practice abstinence or use effective methods of birth control.
  • Are on a stable anti-HIV drug regimen or have not been on any anti-HIV drug regimen for the past 30 days.

Exclusion Criteria

You will not be eligible for this study if you:

  • Are allergic to nandrolone.
  • Have a history of cervical cancer, diabetes, cardiomyopathy or congestive heart failure, or are taking certain medications.
  • Have an active opportunistic (HIV-associated) infection or another major illness within 30 days of study entry.
  • Have an abnormal PAP smear.
  • Have difficulty eating (are on tube-feeding, for example).
  • Have severe nausea, vomiting, or diarrhea.
  • Have Kaposi's sarcoma (unless stable) or are receiving chemotherapy or radiation for any type of cancer.
  • Are pregnant or breast-feeding.
Female
13 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00000854
ACTG 329, 11301
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: K Mulligan
Study Chair: R Clark
Study Chair: J Currier
National Institute of Allergy and Infectious Diseases (NIAID)
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP